A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Search:
Medline
CancerConsultants.com
Both
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$44.82-0.37 (-0.82%)
NVS$53.13-0.16 (-0.3%)
SNY$37.67-0.01 (-0.03%)
GSK$41.530.06 (0.14%)
click here
Cancer News: Renal Cancer: Article   Printable Version 


Renal Cancer News

Nexavar® May Reduce Brain Metastases in Patients with Metastatic Renal Cell Carcinoma

Researchers from France and Poland have reported that Nexavar® (sorafenib) may reduce the incidence of brain metastases in patients with metastatic renal cell carcinoma (RCC). The details of this study appeared early online on October 22, 2009 in the Annals of Oncology.[1] 

Targeted therapies with agents such as Nexavar and Sutent® (sunitinib) have changed the palliative treatment of patients with RCC. However, little has been written about the effects of these agents on brain metastases.

Researchers involved in the current study evaluated the incidence of brain metastases in a subset of patients enrolled in the randomized Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET study). The details of this randomized trial were published in the January 11, 2007, issue of the New England Journal of Medicine. The subgroup analysis included 139 patients: 70 in the Nexavar group and 69 in the control group. The incidence of brain metastases was 3% in the Nexavar group and 12% in the control group (p<0.05). These authors suggest that Nexavar may reduce the incidence of brain metastases.

Comments: These data need to be confirmed by analyzing the entire TARGET study population because the incidences are so low and of borderline statistical significance.

Reference:

[1] Massard C, Zonierek J, Gross-Goupil M, et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Annals of Oncology [early online publication]. October 22, 2009.



© 1998-2007 OncoEd.com All Rights Reserved.

These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein. © 1998-2007 OncoEd, Inc  All Rights Reserved.

These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.





© 1998-2007 CancerConsultants.com  All Rights Reserved.